CYP2D6 and psychotic disorder: Adopting PGx testing in EIP services would allow for exploration of when CYP2D6 genotype has contributed to psychosis drug failure because of ADRs or inefficacy associated with a ‘CYP2D6-PGx antipsychotic’ and enable personalised prescribing of drugs for psychosis to reduce the risk of poor treatment outcomes.